IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (CSC)’s Andrew Cornforth, Ph.D. and Robert Dillman, M.D. are scheduled to speak at two prominent immunology conferences this week. The pair will convene with international scientists and clinicians to share additional details and positive phase II results from CSC’s patient-specific cancer immunotherapy.
